197 related articles for article (PubMed ID: 38457493)
1. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
Abraham BG; Haikarainen T; Vuorio J; Girych M; Virtanen AT; Kurttila A; Karathanasis C; Heilemann M; Sharma V; Vattulainen I; Silvennoinen O
Sci Adv; 2024 Mar; 10(10):eadl2097. PubMed ID: 38457493
[TBL] [Abstract][Full Text] [Related]
2. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
4. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation.
Zhao L; Dong H; Zhang CC; Kinch L; Osawa M; Iacovino M; Grishin NV; Kyba M; Huang LJ
J Biol Chem; 2009 Sep; 284(39):26988-98. PubMed ID: 19638629
[TBL] [Abstract][Full Text] [Related]
5. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
6. A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).
Zhao L; Ma Y; Seemann J; Huang LJ
Biochem J; 2010 Jan; 426(1):91-8. PubMed ID: 19929856
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
Shan Y; Gnanasambandan K; Ungureanu D; Kim ET; Hammarén H; Yamashita K; Silvennoinen O; Shaw DE; Hubbard SR
Nat Struct Mol Biol; 2014 Jul; 21(7):579-84. PubMed ID: 24918548
[TBL] [Abstract][Full Text] [Related]
8. Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation.
Ferrao RD; Wallweber HJ; Lupardus PJ
Elife; 2018 Jul; 7():. PubMed ID: 30044226
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.
Leroy E; Balligand T; Pecquet C; Mouton C; Colau D; Shiau AK; Dusa A; Constantinescu SN
J Allergy Clin Immunol; 2019 Jul; 144(1):224-235. PubMed ID: 30707971
[TBL] [Abstract][Full Text] [Related]
11. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.
Funakoshi-Tago M; Pelletier S; Moritake H; Parganas E; Ihle JN
Mol Cell Biol; 2008 Mar; 28(5):1792-801. PubMed ID: 18160720
[TBL] [Abstract][Full Text] [Related]
12. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
13. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway.
Wei S; Luo C; Yu S; Gao J; Liu C; Wei Z; Zhang Z; Wei L; Yi B
Exp Cell Res; 2017 Dec; 361(2):342-352. PubMed ID: 29102603
[TBL] [Abstract][Full Text] [Related]
18. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
[TBL] [Abstract][Full Text] [Related]
19. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM
Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948
[TBL] [Abstract][Full Text] [Related]
20. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]